Skip to content

Vasopressor Infusion in Cesarean Delivery

Comparison of Two Vasopressor Infusion for Prevention of Post-spinal Hypotension During Cesarean Delivery: A Randomized Controlled Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03248791
Enrollment
120
Registered
2017-08-14
Start date
2017-08-20
Completion date
2022-03-10
Last updated
2021-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section Complications, Spinal Anesthesia

Brief summary

Comparison will be conducted between continuous variable infusions of both drugs (Phenylephrine and Norepinephrine) with starting doses of 0.75 mcg/Kg/min and 0.1 mcg/Kg/min respectively for prophylaxis against Post-spinal hypotension during cesarean delivery.

Detailed description

Maternal hypotension is a common complication after spinal anesthesia for cesarean delivery (CD). Many vasopressors have been used for prevention of post-spinal hypotension (PSH) during CD; however, the optimum protocol for prophylaxis is not established yet. Phenylephrine (PE) is a popular vasopressor used in obstetric anesthesia; however, its use is limited by its marked cardiac depressant nature. Norepinephrine (NE) is a potent vasopressor characterized by both α adrenergic agonistic activity in addition to a weak β adrenergic agonistic activity; thus, NE is considered a vasopressor with minimal cardiac depressant effect; these pharmacological properties would make NE an attractive alternative to PE. In this study, we will compare continuous variable infusion of both drugs (PE and NE) with doses of 0.75 mcg/Kg/min and 0.1 mcg/Kg/min respectively for prophylaxis against PSH during CD.

Interventions

DRUGPhenylephrine

Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.

DRUGNorepinephrine

Norepinephrine variable infusion with a starting rate of 0.1 mcg/Kg/min.

DRUGBupivacaine

Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* full term * pregnant women * scheduled for cesarean section

Exclusion criteria

* pre-ecpamsia * eclampsia * bleeding * cardiac dysfuction

Design outcomes

Primary

MeasureTime frameDescription
incidence of post-spinal anesthesia hypotension30 minutes after spinal anesthesiaDefined as the percentage of patients with decreased systolic blood pressure less than 80% of the baseline reading

Secondary

MeasureTime frameDescription
incidence of severe delivery hypotension10 minutes after deliveryDefined as the percentage of patients with decreased systolic blood pressure less than 80% of the baseline reading
systolic blood pressure2 hours after subarachnoid blocksystolic blood pressure measured in mmHg
diastolic blood pressure2 hours after subarachnoid blockdiastolic blood pressure measured in mmHg
incidence of severe post-spinal anesthesia hypotension30 minutes after spinal anesthesiaDefined as the percentage of patients with decreased systolic blood pressure less than 60% of the baseline reading
APGAR score10 minutes after deliveryAPGAR score of the fetus
incidence of reactive hypertension2 hours after spinal anesthesiaDefined as the percentage of patients with increased systolic blood pressure more than 80% of the baseline reading
heart rate2 hours after subarachnoid blocknumber of heart beats per minute

Countries

Egypt

Contacts

Primary ContactAhmed Hasanin, Professor
ahmedmohamedhasanin@gmail.com+201095076954

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026